The AMR Challenge
Antimicrobial resistance is not only a science problem. It is a delivery problem, a market problem, and a coordination problem.The world has focused on developing new antimicrobial medicines. But without a viable way to deliver them, innovations cannot reach the patients who need them – or generate the returns needed to sustain development pipelines.
Antimicrobial resistance is on track to become one of the world’s deadliest health threats, with the burden falling hardest on low- and middle-income countries. Yet the global response has focused largely on R&D, leaving the delivery system fragmented.
The failure compounds:
- Essential first-line medicines are inconsistently available.
- Clinicians turn to second-line drugs when first-line options stock out.
- Overuse accelerates resistance.
- Reserving medicines become more necessary.
- Manufacturers have little commercial incentive to register and maintain supply in markets which are small or have low value.
- Governments overspend – while patients experience worse outcomes.
This is the string of problems Aranda was created to solve.
What is missing is not just more money or more molecules. It is the architecture to connect supply, surveillance, stewardship, and financing into something a government can actually buy and deliver.
Why antimicrobials require a different model
Antimicrobials create an unusual market challenge.
They must be available when patients need them, but they must also be used carefully. They are often low-cost, short-course therapies, which makes it difficult for innovators to recover investment through traditional per-dose pricing. At the same time, the more these medicines are used, the faster resistance can develop.
That creates a structural tension: the world needs antimicrobial innovation, but the conventional market rewards volume – and volume makes the problem worse.
Aranda resolves that tension by separating revenue from usage. Governments pay a fixed subscription for diagnostics and medicines, bundled together with stewardship and surveillance to ensure medicines are used appropriately.
Since we provide a flat rate subscription, Aranda takes usage risk on medicine volumes while governments can rest assured that incentives to ensure supply consistency and appropriate use are continually in place, and not subject to the vagaries of finance ministries’ yearly budget processes.
Governments and industry can’t solve it alone
Governments are central to antimicrobial access, but the countries facing the greatest burden often have the least capacity to coordinate supply, clinical use, surveillance, financing, and industry participation on their own.
Industry faces the other side of the problem. Manufacturers need sustainable revenue, predictable demand, and protection for global pricing architecture. Without that, many cannot justify the regulatory, supply, pharmacovigilance, and market development investments required to serve smaller or less predictable markets.
Any viable solution has to align both.
Aranda creates the structure for governments and industry to participate in the same system, with shared incentives, clear accountability, and measurable outcomes.
Aranda addresses the full chain of failure
Aranda’s system:
- Guarantees access to antimicrobial medicines and diagnostics
- Supports appropriate use through stewardship
- Tracks resistance, usage, stock levels, and outcomes through surveillance
- Gives governments predictable multi-year fixed-rate pricing with no escalation
- Generates sustainable revenue for manufacturers and innovators
- Reduces long-term health system costs
- Creates a path away from perpetual donor dependence
- Improves population health outcomes
Our ambition is large because the problem is large. But our approach is practical: a fixed-price subscription, designed specifically for each country and delivered locally, with aligned incentives across the value chain.
CONNECT WITH US
Aranda is building an economically-viable approach to solving one of global health’s most urgent and intractable problems.